Richard A Scolyer
Overview
Explore the profile of Richard A Scolyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
682
Citations
19562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Shklovskaya E, Satgunaseelan L, Mao Y, Pires da Silva I, Perry K, et al.
Nat Med
. 2025 Feb;
PMID: 40016450
Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many...
2.
Newell F, Pires da Silva I, Johansson P, Menzies A, Wilmott J, Addala V, et al.
Cancer Cell
. 2025 Feb;
43(3):563.
PMID: 39919735
No abstract available.
3.
Lo S, Varey A, Chng S, Scolyer R, Thompson J
J Natl Cancer Inst
. 2025 Feb;
PMID: 39913373
No abstract available.
4.
Wu Z, Nickel B, Boroumand F, Elder D, Ferguson P, Scolyer R, et al.
BMJ Open
. 2025 Jan;
14(12):e089558.
PMID: 39806624
Introduction: A diagnosis of melanoma in situ presents negligible risk to a person's lifespan or physical well-being, but existing terminology makes it difficult for patients to distinguish these from higher...
5.
Dummer R, Robert C, Scolyer R, Taube J, Tetzlaff M, Menzies A, et al.
Nat Med
. 2025 Jan;
31(1):144-151.
PMID: 39775043
Neoadjuvant immunotherapies have shown antitumor activity in melanoma. Substudy 02C of the global, rolling-arm, phase 1/2, adaptive-design KEYMAKER-U02 trial is evaluating neoadjuvant pembrolizumab (anti-PD-1) alone or in combination, followed by...
6.
Dempsey K, Ho G, Lo S, McKeown J, Watts C, Cust A, et al.
JAAD Int
. 2024 Dec;
18:90-100.
PMID: 39687200
Background: Factors associated with nonadherence to guideline-recommended complete excision of suspicious cutaneous lesions are unclear. Objective: The purpose of this study was to analyze patient, melanoma, and clinician factors associated...
7.
Clarke E, Magee D, Newton-Bishop J, Merchant W, Insall R, Maher N, et al.
Arch Pathol Lab Med
. 2024 Dec;
PMID: 39663822
Context.—: The current melanoma staging system does not account for 26% of the variance seen in melanoma-specific survival, therefore our ability to predict patient outcome is not fully elucidated. Morphology...
8.
Lo S, Williams G, Cust A, Ollila D, Varey A, Chng S, et al.
JAMA Dermatol
. 2024 Dec;
161(2):167-174.
PMID: 39661373
Importance: Most patients who present with primary cutaneous melanomas have thin tumors (≤1.0 mm in Breslow thickness, ie, pT1a and pT1b). Although their prognosis is generally considered to be excellent,...
9.
Reijers I, Menzies A, Lopez-Yurda M, Versluis J, Rozeman E, Saw R, et al.
Eur J Cancer
. 2024 Nov;
214():115141.
PMID: 39602990
Background: Pathologic response following neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma serves as a surrogate marker for long-term outcomes. This may support more personalized, response-directed treatment strategies. Methods:...
10.
Melhoranse Gouveia B, Ferguson P, Lo S, Collgros H, Martin L, Sinz C, et al.
J Eur Acad Dermatol Venereol
. 2024 Nov;
39(3):555-565.
PMID: 39535326
Background: Lentigo maligna (LM) is a growing problem worldwide and the main type of melanoma in situ in some Caucasian populations. It presents as a spectrum from atypical intraepidermal melanocytic...